

**LATTICE™**Leading Awareness To action Through  
Implementation of Cardiometabolic Efforts

# Annual Registry Data Illuminates the State of Care\*

Learn more about the cvMOBIUS2 project

**Project Lead:** Ann Marie Navar, MD, PhD **Project Contact:** ann.navar@utsouthwestern.edu

## Aim of Project

Examine and track lipid-lowering therapy (LLT) utilization and low-density lipoprotein cholesterol (LDL-C) levels in adults with atherosclerotic cardiovascular disease (ASCVD) seen across a maximum of **25 health systems over 5 years**. Annual sub-analysis will evaluate **factors associated with achievement** of appropriate LDL-C lowering in various cohorts of adults with ASCVD.

**Status** **ONGOING**

**Start:** January 2022 | **Anticipated completion:** Q1 2026

**Anticipated number of practice settings:** 16 Integrated Delivery Networks (IDNs) (max 25)



## The Importance of Registry Data

- LDL-C is one of the key modifiable risk factors for ASCVD
- Ordering of guideline-recommended therapies can reduce LDL-C to target level and reduce cardiovascular risk for patients with ASCVD

## Methods for Success

**Performance Dashboard**



Prospective registry study leveraging Patient-Centered Clinical Research Network (PCORNET) electronic health record (EHR) system to examine LLT utilization and LDL-C levels

## Participation Criteria

For sites/systems to be eligible for project participation, they must utilize the PCORNET EHR system, be willing to provide data, and be willing to work with the Duke Clinical Research Institute (DCRI).

## Anticipated Outcomes



Increase proportion of patients with ASCVD that are identified and, where appropriate, treated according to ACC/AHA guideline recommendations for LLT



Understand baseline characteristics of people with established ASCVD who initiate non-statin LLTs versus those who don't initiate non-statin LLTs



Improve clinical outcomes in adults by LDL-C level at baseline and over time



Understand health system heterogeneity of utilization of non-statin LLTs



Track lipid trajectories in patients with ASCVD by treatment status



Recognize novel patterns in LLT uptake

\*This is a collaborative study between a LATTICE™ Consortium expert and Amgen.

# Introducing the LATTICE™ Consortium:\*


Leading Awareness To action  
Through Implementation of  
Cardiometabolic Efforts



## A network of experts committed to improving the treatment of cardiometabolic disease

**LATTICE™ Consortium** is a first-of-its-kind community addressing cardiometabolic patient needs through implementation efforts. By sharing collectively-learned tools and methodologies, we can improve the effectiveness of cardiometabolic patient care at scale.

### What you'll find on the LATTICE™ Consortium website:



**Learn about us:** Get to know our experts, our vision, how implementation science can improve health outcomes, and current projects



**Tools and resources:** Find tools and resources that can be adopted or adapted to improve the quality of cardiometabolic patient care



**Connect:** Meet implementation science peers at both virtual and live events for education and sharing sessions



**Submission portal:** We welcome new and novel project proposals on the study of implementation methodologies

**LEARN**  
MORE ABOUT US 

VISIT [LATTICEConsortium.com](https://LATTICEConsortium.com) OR SCAN



\*LATTICE™ Consortium is a coalition of independent experts with a shared goal to address cardiometabolic patient care through evidence-based tools and methodologies. The coalition is led by its experts, whose collective efforts are responsible for the programs and activities in furtherance of the shared goal. Each LATTICE Consortium expert's efforts are valued and equally considered.